$IQV · The Compound · 2026-10-27
他不喜欢 IQVIA 的图表形态，也看不到看涨理由，因其合同研究业务面临众多竞争厂商；即便 IQV 在六个月内回补 213 的 7 月缺口，他也不会投资。
逐段跳播
好。下一个。我们上周写过这只股票。这是 IQVIA。我保证你们之前都没听说过它。这些名字我一个都没听说过。我是说，我听说过它。我不知道这些股票是什么。Shawn 和我做这件事的目的，是想让人们了解他们以前从未听说过的股票。
不，我几乎可以肯定，我是唯一在 CNBC 上提到过这只股票的人。这家公司从1954年就开始运营了。我不喜欢，我不喜欢这只股票的形态。这里有很多很多卖家。我看不到你所看到的东西。
它是一家为制药公司服务的合同研究组织。他们利用数据帮助制药公司开发药物。他们可能拥有地球上最重要的私人医药数据库。好吧，这会在未来六个月内回补缺口，213处的7月缺口。记住这一点。
我不会参与，如果那样发生，我不会投资它。你能看到明显的止步点就在缺口处，对吧？
Good. the next. We wrote about this stock last week. This is IQVIA. I guarantee you that none of you have ever heard of it before. I have never heard of any of these names. I mean, I've heard of it.
I don't know what these stocks are. The goal of this exercise that Shawn and I are doing. We want people to learn about stocks they've never heard of before. No, I'm almost certain I'm the only person who mentioned this stock on CNBC.
This company has been operating since 1954. I don't like, I don't like the shape of this stock. There are many, many vendors here. I don't see what you see . It is a contract research organization for pharmaceutical companies.
They help pharmaceutical companies develop drugs using data. They may possess the most important private pharmaceutical data library on Earth. Well, this will close the gap, the July gap at 213, over the next six months.
Keep that in mind. I won't be there, I won't invest in it if that happens. You can see where the obvious stopping point is at the gap, can't you ?